Recently, the first clinical study result of the Class I innovative drug YK-029A, originally developed by Puhe Biopharma, was included in the 2023 ASCO poster discussion. The poster presentation and on-site poster discussion session were held on June 4 in the United States time. Professor Duan Jianchun, from Professor Wang Jie's team at the Cancer Hospital of the Chinese Academy of Medical Sciences, attended and gave a keynote presentation.